This improvement might correlate with the slightly enhanced efficacy in protecting against lower respiratory tract infection and lung pathology during the early phase (day 6 post-exposure) following homologous challenge with the Omicron variant in K18-hACE2 mice. The gene discussed is KRT18; the disease is Recurrent lower respiratory tract infections.